Standard treatment for metastatic colorectal cancer (mCRC) typically involves antiangiogenic therapies, which block angiogenesis, the formation of new blood vessels, thereby starving cancer cells. Anlotinib, a multitarget tyrosine kinase inhibitor, works by targeting VEGFR1-3, which hinders tumor metastasis and growth. In study results to be presented this weekend at the 2021 Gastrointestinal Cancers Symposium, anlotinib demonstrated efficacy in patients with previously treated mCRC. ALTER0703, ...